GSK

About GSK

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whoop... Read More

GSK Company Stats

Industry: Drugs & Biotechnology

Founded: 2000

Headquarters: London

Country/Territory: United Kingdom

Chief Executive Officer: Emma N. Walmsley

Employees: 69,400

Forbes Lists

#162

World's Top Companies for Women (2023)

#198

World's Best Employers (2023)

America's Best Employers By State (2023)

#109

Best Employers for Women (2023)

#187

Global 2000 (2023)

#215

Best Employers for Diversity (2023)

#176

America's Best Large Employers (2023)

#237

Canada's Best Employers (2023)

#97

Top Regarded Companies (2019)

#61

Top Multinational Performers (2017)

#52

Innovative Growth Companies (2016)Dropped off in 2017

GSK Financial Summary

Select list year

Revenue

$35B

Assets

$72.5B

Profits

$5.3B

Sources

FactSet, Bloomberg, S&P Cap IQ; Forbes.

GSK (GSK) Stock Price Performance

SummaryAdditional DataAnalystsHistorical Quotes

Key Data

Previous Close

36.17

Open

36.04

Day’s Range

35.80 x 36.08

Volume

2,343,680

52 Week Range

33.20 x 38.32

Market Cap

$58.39B

P/E Ratio (ttm)

9.67

Forward P/E

9.29

Diluted EPS (ttm)

1.48

Dividends Per Share

0.56

Dividend Yield

3.92%

Ex-Dividend Date

Nov 16, 2023

Valuation Measures

P/E Ratio (ttm)

9.67

Forward P/E

9.29

Price to Sales (ttm)

1.95

Price to Book Value (ttm)

4.42

Price to Tangible Book Value (ttm)

N/A

Total Enterprise Value to EBIT (ttm)

9.41

Total Enterprise Value to EBITDA (ttm)

7.84

Total Enterprise Value to Total Revenue (ttm)

2.43

Markets data provided by S&P and by Xignite

Profitability Metrics

Gross Margin (ttm)

72.14%

Operating Margin (ttm)

25.83%

Net Margin (ttm)

20.48%

Return on Assets (ttm)

7.90%

Return on Equity (ttm)

61.26%

Revenue and Earnings Metrics

Revenue (ttm)

$29.65B

Revenue Per Share (ttm)

7.33

Revenue Growth (y/o/y)

2.16%

EBITDA (ttm)

$9.19B

EBITDA Growth (y/o/y)

-8.93%

Diluted EPS (ttm)

1.48

Diluted EPS Growth (y/o/y)

78.45

Cash and Debt Metrics

Total Cash

$6.68B

Total Cash Per Share

0.78

Total Debt

$20.84B

Total Debt/Equity

165.16%

Current Ratio

0.95

All values as of most recently reported quarter unless otherwise noted.

Markets data provided by S&P and by Xignite

Consensus Recommendation

Outperform

Consensus Price

17.27

Range of Price Targets

11.90 to 25.30

Range of EPS

1.37 to 1.63

Consensus EPS

1.54

Consensus Revenue

$30.78B

Range of Revenue

$29.75B to $31.96B

Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.
EPS and Revenue estimates are for the next 12 months.

Markets data provided by S&P and by Xignite

DATE	OPEN	HIGH	LOW	CLOSE	ADJUSTED CLOSE	VOLUME
Dec 7, 2023	14.41	14.49	14.27	14.33	14.33	1,055,561
Dec 6, 2023	14.43	14.54	14.31	14.40	14.40	8,779,046
Dec 5, 2023	14.51	14.64	14.31	14.40	14.40	4,490,493
Dec 4, 2023	14.37	14.58	14.37	14.55	14.55	4,952,435
Dec 1, 2023	14.26	14.38	14.19	14.36	14.36	5,240,719
Nov 30, 2023	14.06	14.27	13.96	14.19	14.19	1,253,121
Nov 29, 2023	14.09	14.10	13.96	14.01	14.01	2,873,205
Nov 28, 2023	14.08	14.24	13.95	14.12	14.12	5,168,417
Nov 27, 2023	14.24	14.29	14.14	14.14	14.14	2,685,048
Nov 24, 2023	14.22	14.30	14.11	14.23	14.23	4,716,875
Nov 23, 2023	14.09	14.25	14.04	14.21	14.21	4,771,854